Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The lung cancer presentation is what really interests me the most.. They must be really close for the start of the '113 trial..
Triple top, indeed!
The Ariad Stock Price model:
Hardly No revenue, will lose $2.xx this year and $3.xx next year..
http://finance.yahoo.com/q/bc?s=VRUS&t=2y&l=on&z=l&q=l&c=
The action of a new high on absolutely HUGE volume will bring in another class of investor now.. The IBD crowd.. Let them play with it for awhile..
I can't believe this little rascal wants to do it...
I've had enought of this exciting dialog, and, I'm going flying tomorrow, so, I bid you all a pleasant evening..
Nope, I didn't say that. At this time, it would not be used as a first line treatment.. Harvey is INDEED targeting the T mutation for Pona. In fact, he struck a partnership with another biotech to develop a test for this T mutation..
Nope. Never said that..... read the PR from Ariad on Pona to better understand, I would suggest..
Nope.. I do not short Biotech.. You can see what happened to the shorts here..
Harvey is not gonna rush this Asian partner.. Every day, the partnership becomes more valuable, and with cash available to fund operations into 2012, there is no reason to partner now.. Just think of the value of Pona after December 2011......
Nope. They are targeting the T315I mutation in CML, which represents ~15-20% of all mutations.
Lots of short covering today.. Let's see what happens over the next 5 trading days..
Nope. Front line is not in the picture right now (may be 3 to 4 years out). Look, if we only can treat 20% of ALL mutations for CML, that is not a very big market.. What % of CML patients end up with a mutation?
Nope. Front line is not in the picture right now (may be 3 to 4 years out). Look, if we only can treat 20% of ALL mutations for CML, that is not a very big market.. What % of CML patients end up with a mutation?
Jefferies provides color on Rida with endometrial cancer
Jefferies Provides Color on Ariad Pharmaceuticals, Buy
By Emily Austin
Benzinga Staff Writer
June 06, 2011 7:44 AM
Jefferies provided color on Ariad Pharmaceuticals (NASDAQ: ARIA). In a research report published today, Jefferies commented on the company's drug ridaforolimus.
In the report, Jefferies states, "Given that there are no established options for 2nd-line endometrial cancer, we view ridaforolimus represents a potential treatment option. First-line therapy for endometrial cancer is hormonal therapy (progestin) or plantinum-sentisitve chemotherapy."
At the moment, Jefferies has a Buy rating and a price target of $11 placed on the company's stock. On Friday, Ariad had a difficult trading session, losing 5.51% to close the week at $7.89. Its shares regained some of its Friday's losses in today's pre-market trading, however, rising 1.77% to $8.03.
.
Read more: http://www.benzinga.com/analyst-ratings/analyst-color/11/06/1140120/jefferies-provides-color-on-ariad-pharmaceuticals-buy#ixzz1Og51qfvw
Is this going to make a DNDN Q1 2009 type move?
http://finance.yahoo.com/q/bc?s=DNDN&t=5y&l=on&z=l&q=l&c=
I agree with Ariad up nicely..but EXEL is sh*t, imho.. Too many deaths
I bet 3 million of the 6.8 million shares traded today were short covering..
Next event should be the start of the '113 trial, which Harvey has relentlessly stated should begin in, "mid-year"..
EXEL to get hammered again, imho..
Thank the good Lord that Timmy C is there..
FTH, I'm just talking about the Rida contribution to their business, NOT the reported earnings..
The SUCCEED presentation at ASCO had no subset analysis??
Didn't have to..
This is huge potentially for Ariad.. Let's see if Mr. Market can connect the dots...
Mr. Market will take a little time to figure this out, I reckon.. The clinical trial of '113 should begin in the next 30 days or so..
I can promise you Ariad will move on this news once they connect the dots...
http://finance.yahoo.com/news/Study-Pfizer-lung-cancer-pill-apf-1393441363.html?x=0&sec=topStories&pos=2&asset=&ccode=
Was Fidelity lightening up?????????????????????????????
Today, the DJIA should be down 600 points, and it isn't.. What on earth is supporting this thing?
With 1/3 of AML patients getting the FLT3-positive mutation, I would say the market is there.. And, just like I mentioned earlier, what is the next step for a phase 2 trial, as the closing remarks indicate that they are going to persue this..
I think the AML data from Ariad tomorrow will set the stage for the SP up to June 6th Rida data..
TOMORROW, could the results of the phase 1 trial with Pona on AML, result in an announcment of another pivotal phase 2 trial for AML??
Next up, happening tomorrow:
Ponatinib
Title: Ponatinib in patients with acute myeloid leukemia (AML): preliminary findings from a Phase 1 study in hematologic malignancies
Date & Time: Friday, June 3, 2:00 PM - 6:00 PM CT (Poster discussion session)
Abstract: #6518
Presenter: Moshe Talpaz, M.D. (University of Michigan, Ann Arbor, MI)
Location: E450b
This correction in the market has way go lower.. I know some have bought here recently, but with the 10 Year treasury now at 2.94%, the stage is set for a SIGNIFICANT slowdown in the world economy.. QE2 just didn't work.. The ASCO bounce in Ariad shares (because I expect the news is good) in the next several days could be a time to lighten up, imho..
The market is down 280 points, the banks and investment firms have been slaughtered, the 10 year is below 3%, materials and grains have been crushed for days, Greece is going to definately default, and you think this is Ariad specific?
Busted on high volume..didn't hold..
The ten year US government bond tells you all you need to know. The yield has plunged to 2.97% as of today.
Now we have June 3rd, 6th, and 8th to look forward to.... Great way to start a new month..
The OS should be good for Rida. As Harvey said, unfortunately, the patients in the non-Rida arm will end up passing away over the course of the trial